10 minute read
SYNLAB Nigeria
CHANGING THE NARRATIVE
Advancing an accessible agenda for public health care, SYNLAB Nigeria is committed to delivering quality pathology services with an unparalleled customer focus. CEO Kenneth Okolie tells us more
Writer: Phoebe Harper | Project Manager: Callam Waller
At the end of the day, quality healthcare is not equitably distributed, and last I checked, it is a basic human right.” The powerful opening words of Kenneth Okolie capture the mission that is at the very core of Nigeria’s leading pathology provider, SYNLAB Nigeria (SYNLAB).
The Nigerian branch of the company operates as a key part of the wider SYNLAB Group, reputed as the largest diagnostic service provider in Europe with a presence in over 40 countries and employing over 20,000 people.
– KENNETH OKOLIE, CEO, SYNLAB NIGERIA
With a strategic focus on providing quality pathology services for human health, SYNLAB is well-established as the market leader in Nigeria with over 32 client centres that include 11 laboratories.
As CEO of the company, Kenneth is passionate about making quality diagnostic services as accessible as possible across Nigeria and West Africa, furthering the sector to become comparable with the developed world.
“Our key priorities revolve around creating more access for people to quality medical diagnostics which is made available as affordably as possible. By understanding that we’re in a resource-challenged environment, we are aware of the obligation this puts on us to ensure we improve access.”
IDENTIFYING OPPORTUNITIES IN CHALLENGES
Both Kenneth and SYNLAB are fully alert to the challenges that prevail in Nigeria’s healthcare sector. But far from fatalistic and stoically undeterred, such impediments are rather seen as a gateway to opportunity.
“To an average person the industry appears filled with challenges, but it’s more a case of opportunity,” he tells us. “There are significant infrastructural issues in that the average public health facility is poorly built, managed, and equipped.
“We also have a lot of logistical challenges with poor road networks and a lack of power, and in the midst of all this, you’re still expected to deliver efficient and effective healthcare!”
Sysmex
SICKLE CELL DISEASE SITUATION IN NIGERIA: According to current WHO statistics, 150,000 babies are born with sickle cell disease annually, making Nigeria the highest ranking globally, and certain to increase by 54% in 2050, with a high prevalence rate of childhood mortality and morbidity. Lack of early diagnosis especially in newborn and young children has posed a significant problem in early identification and medical interventions.
Sysmex has introduced HemoTypeSCTM, a rapid diagnostic tool that can help detect Hb A, S and C at an early stage of the disease, so they can have specific treatment.
• The use of HemoTypeSC does not require electricity, No machine/ equipment, No buffer, No reagents.
Thereby making Hb Genotype test suitable for low resource income areas and inexpensive for all categories of persons. • With HemoTypeSCTM, newborn
Hb Genotype test is possible at birth meaning it can test neonates without having to wait for 6 months to 1year when the levels of fetal haemoglobin is reduced.
HemoTypeSC does not have any form of interference with Fetal
Haemoglobin. This feat makes early detection of Sickle Cell Disease possible and as such Sickle Cell patients can be managed early thereby eradicating the incidences of early deaths attributed to lack of early detection and management.
We advocate making Newborn Hb Genotype testing a national and state policy in all healthcare facilities thereby making early detection of Sickle Cell Disease possible at birth and as such Sickle Cell patients can be managed early thereby eradicating the incidence of early deaths attributed to lack of early detection and management.
www.sysmex-wca.com
Despite this fraught context, Kenneth acclaims that this creates a window for the private sector to intervene.
“The bigger problem that we must address is how to solve these problems without the cost being passed to the client or patient.
“At the core of what we are trying to do in Nigeria is understanding the challenges that bring an opportunity to correct the narrative with regards to healthcare. We don’t believe that we can fix the system, but we believe that we can play a role,” he shares confidently.
In fulfilling these aspirations, SYNLAB pursues an agenda of ambitious growth to expand its footprint and make its quality, customer-centric services as widely accessible as possible.
“One of the crucial things that we’ve decided to do at a very senior level is to focus on making quality healthcare and pathology services available and accessible.
“With this as the backdrop, creating accessibility means that we need to get ourselves into spaces where we are not present since we want to ensure people have access to quality laboratory test results and supporting services.”
This expansion is imperative to the collective health of the nation, as laboratory services play a critical role in clinical and patient care management. Indeed, a late, or a wrong result, can have serious implications for a patient.
HARNESSING TALENT
As an extension and result of the challenges outlined above, Nigeria is a classic example of ‘brain drain’ in practice, as many of the country’s trained practitioners and medical professionals selectively pursue employment opportunities in Europe or America.
BD
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care.
The company develops innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers.
BD and its 75,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues.
BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.
For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.
bd.com
“You can’t blame them!” quips Kenneth. “I think that second only to oil, human resources are probably Nigeria’s biggest export.”
In a bid to combat this and foster local talent, SYNLAB has begun partnering with strategic universities to keep Nigerian medical professionals on native soil. “If I can partner with universities, and influence their training at a foundational level, we’ll be able to create better-skilled employees who are knowledgeable about both modern applications of medicine, and theoretical aspects,” he explains.
“The average time to train a person at SYNLAB before you can attend to patients and get into full operations is six months. If I am losing people to the developed world at a fast rate, it impacts my operations.”
It is a career pathway founded on practical training that is not dissimilar to Kenneth’s own, although the practice has evolved significantly. “Having grown through the system, what I learned in school and what I see on a day-to-day basis are worlds apart.
Inqaba Biotec West Africa Ltd (IBWA)
Our expertise in the life science industry was put to test during the COVID-19 pandemic.
As a result of our successful involvement with the diagnostic market, offering complete lab setup to capacity building, our renewed mission is to facilitate life science research and diagnostics in West and Central Africa by making it possible for researchers and diagnosticians in the region to be at par with their counterparts in other parts of the world. This is evident in the range of products we offer in-house and through our renowned partner brands.
www.inqababiotec.africa
“Working in a company like SYNLAB offers you access to the best-in-class updates in science and technology. If my team or those that have the opportunity to work at SYNLAB are the only ones that can access this kind of information, the development we’re striving to drive will be extremely slow. But if we’re able to give many people access to this same information, even if they are not employees, they may be able to replicate a path of what we’re doing in other places. In that way, we drive development.”
THE DIGITAL DIFFERENCE
Working in conjunction with the talent of human resources is SYNLAB’s advanced incorporation of digitalisation as the foundation of its operations and a critical element in streamlining efficiency for the services it offers.
The company is one of the most digitally focused pathology service
Inqaba Biotec West Africa Ltd (IBWA) is a subsidiary of Inqaba Biotechnical Industries (Pty) Ltd, South Africa. The company was incorporated in 2014 and within Ibadan, Nigeria.
IBWA aims to provide genomics products and services to researchers across West and Central Africa. In 2015, we setup our first office in Nigeria at the Bioscience Unit of IITA. In 2018, we moved to our own premises which is located right opposite IITA.
As a company, our mission is simple – to facilitate life science research in West and Central Africa by making it possible for researchers in the region to be at par with their counterparts in other parts of the world.
www.inqababiotec.africa
Celebrating 20 years of uniqueness!
providers in Nigeria, but what separates SYNLAB in this respect, is how digitalisation is entirely tailored to the customer, as the central tenet around which the entire business revolves.
“Our focus, 100 percent of the time, is how can we help our customers – doctors, patients, corporate organisations, any customer we have, meet their outcome. Every customer has a unique set of expectations, and that philosophy is what drives us in improving our digitalisation efforts,” says Kenneth.
These efforts encompass management systems and web interfaces to create a paperless system centred on accuracy and efficiency. This eliminates the risk of wrong requests being received by the laboratory and reduces the waste of both time and resources.
“We put time into reviewing our processes and seek ways to automate manual processes. We have been able to innovate in how we can better improve our operations and customer engagement, from the way they order their tests, down to how they receive their results.
“SYNLAB is consistently looking for ways to improve – there is no state of perfection, there is only a state of constant improvement.”
In an age where digitalisation is a common offering for an increasing number of businesses, SYNLAB’s combination of this with unparalleled customer service and an intimate understanding of their clients makes all the difference.
“As a business, it is possible to be functionally responsive, but psychologically non-responsive.
“Anybody could copy our digital software, but because there is a reason behind our action, you cannot copy the soul behind what we do.”
A VISIONARY FUTURE
continue to grow as the company champions its vision of providing quality laboratory services to as wide an audience as possible in Nigeria.
“We are helping to build a new way of seeing things. We understand that the actions that we are taking will inspire others to join in and contribute. I want to look back in 20 years and say, we did this, we caused the snowball to start rolling,” closes Kenneth.
“We want to be the organisation that inspired change and a new generation to believe that what is possible in the developed world is also possible in Nigeria. By doing this, we are helping to shape a new narrative.”
SYNLAB NIGERIA
Tel: +234 700 079 6522 ng.enquiry@synlab.com www.synlab.com.ng
